Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | KDM5A | P29375 | 3/20 | 0.59 |
| ▸ | KDM5C | P41229 | 3/20 | 0.59 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.59 |
| ▸ | ALKBH5 | Q6P6C2 | 2/20 | 0.59 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.59 |
| ▸ | ASPH | Q12797 | 2/20 | 0.59 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.59 |
| ▸ | KDM4A | O75164 | 2/20 | 0.59 |
| ▸ | KDM6B | O15054 | 1/20 | 0.59 |
| ▸ | TET3 | O43151 | 1/20 | 0.59 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.59 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.59 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.59 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.59 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28376364 | 0.77 | KMT2A (0.57) | KDM5BKDM4EKDM5AKDM5CKDM4C | |
| SCHEMBL8358422 | 0.77 | MMP13 (0.68) | ALDH1A1LMNAHTTSMN1; SMN2MMP13 | |
| SCHEMBL72377 | 0.77 | KDM5C (1.00) | KDM5BKDM4EKDM5AKDM5CKDM4C | |
| SCHEMBL29382783 | 0.77 | KDM5C (1.00) | KDM5BKDM4EKDM5AKDM5CKDM4C | |
| SCHEMBL97001 | 0.77 | KMT2A (0.68) | ALDH1A1MAPTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL12252466 | 0.77 | KMT2A (0.51) | KDM5BKDM4EKDM5AKDM5CKDM4C | |
| SCHEMBL3530258 | 0.76 | KMT2A (0.64) | KMT2AMMP13RAB9AMAPK1NPC1 | |
| SCHEMBL9585979 | 0.75 | FTO (0.96) | KDM5BKDM4EKDM5AKDM5CKDM4C | |
| SCHEMBL2276257 | 0.75 | KDM5C (0.96) | KDM5BKDM4EKDM5AKDM5CKDM4C | |
| Hydrochloric Acid SCHEMBL10778857 | 0.75 | KDM5C (0.96) | KDM5BKDM4EKDM5AKDM5CKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362033-B1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-04 | — | — | EP | claimed |
| US-7015237-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-03-21 | — | — | US | claimed |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2004-10-21 | — | — | US | claimed |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | claimed |
| EP-1362033-B1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7015237-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-03-21 | — | — | US | disclosed |
| EP-1530475-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-6881743-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-04-19 | — | — | US | disclosed |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2004-10-21 | — | — | US | disclosed |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| WO-2004006931-A2 | PHARMACEUTICAL COMPOSTIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-1362033-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | disclosed |
| WO-2002064568-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | KDM5B 348/4885KDM4E 476/4885KDM5A 642/4885 |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | KDM5B 752/4885KDM4E 991/4885KDM5A 899/4885 |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | KDM5B 627/4885KDM4E 812/4885KDM5A 767/4885 |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP13, MMP11, MMP10 | KDM5B 418/4885KDM4E 559/4885KDM5A 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.